CDX2 and neuroendocrine carcinoma: The molecular mechanisms behind the enrichment of CDX2 loss in MSI-H tumours and rather benign (medullary CRC) or highly aggressive (MANEC/NEC) morphologic subtypes as well as in right-sided CRCs should be explored in further studies to potentially address potential therapeutic implications.